AstraZeneca drug may halt development of world’s fourth leading cause of death

Share this article:
The main ingredient in AstraZeneca's inhaler treatment Pulmicort may help against the development of emphysema and other forms of lung disease, according to new research conducted on smokers with chronic obstructive pulmonary disease (COPD).
Data revealed that Pulmicort's active ingredient, budesonide, shows a 50 percent slower decline in lung density in smokers with COPD, compared to patients taking a placebo. The trial was carried out on 254 smokers with moderate to severe COPD, who were followed for two to four years, during which their lung density was measured. 
It is estimated that there are 600 million COPD sufferers worldwide, making it the world's fourth-leading cause of death. Emphysema, a condition in which lungs are irreversibly and permanently over-inflated, is a form of COPD.
AstraZeneca also markets the inhaler Symbicort for COPD, which combines Pulmicort's budesonide with a long-lasting bronchodilator, formoterol.
The company plans to launch Symbicort, which has experienced strong growth in Europe, in the U.S. for the treatment of asthma later this year.
Share this article:

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.